The Gut Onc Lab Podcast

On this in-person episode of The Gut Onc Lab podcast, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal welcome world-renowned BRCA specialist Dr. Kim Reiss to dismantle the historic view of pancreatic cancer as a monolithic, chemo-only disease. The group dives deep into the 5% to 9% of pancreatic ductal adenocarcinoma (PDAC) patients harboring germline or somatic homologous recombinatio...

In this special in-person episode filmed straight from the floor at ASCO 2026, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal welcome guest Dr. Arvind Dasari (MD Anderson) to discuss why colorectal cancer is officially having its precision medicine moment. From the epidemic of young-onset disease to the frontline tracking of ultra-specific biomarkers, the panel discusses why molecular...

With the 2026 ASCO Annual Meeting just days away, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down for a rapid-fire, "mouth-to-butt" preview of the most practice-altering abstracts hitting the floor in Chicago. Armed with top-line press releases and early data, the team highlights their top three high-stakes selections across the entire GI tract. Key previews include: The Upper...

In this landmark fifth episode of The Gut Onc Lab, Drs. Nicholas Hornstein and Timothy Brown welcome their first guest, radiation oncologist Dr. Nina Sanford, to discuss one of the most significant shifts in modern oncology: Organ Preservation. Historically, esophageal and gastric cancers have required highly morbid, "life-changing" surgeries. Today, the team explores how we can leverage advanced...

In this episode of The GutOnc Lab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal break down MSI-High GI cancers. A cancer diagnosis is never good news—but this is a setting where tumor biology meaningfully changes what’s possible, with immunotherapy offering real potential for durable responses and even cure.    Key discussion points include: MMR vs. MSI: A diagnostic primer on the d...

Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal break down the blockbuster press release from Revolution Medicine regarding their Phase 3 trial, RASOLUTE 302. For years, KRAS was the "compact, smooth" molecule that defied targeted therapy, but the era of the molecular glue has officially arrived.               Understanding the Breakthrough: The hosts emphasize the shift from "OFF" inh...

Drs. Hornstein, Brown, and Grewal discuss how Claudin 18.2 has quickly become an important actionable biomarker in upper GI cancers, with zolbetuximab now entering frontline treatment for selected HER2-negative, microsatellite-stable patients. They review the key phase 3 data supporting its use, while emphasizing that the major challenge in practice is managing the significant nausea and vomiting...

In the second episode of The Gut-Onc Collab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal tackle the explosive growth of targeted therapies in the Upper GI space. The team dives deep into the "how" and "when" of treating HER2-positive and HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinomas, moving from perioperative care to the second-line setting.   Key Takeaw...

In this inaugural episode of The Gut Onc Lab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down to break down the most impactful data from the 2026 ASCO GI Cancers Symposium. From bispecific antibodies in upper GI to the long-awaited "drugging" of KRAS in pancreatic cancer, the team discusses how these latest clinical findings are ready to move from the podium to the clinic.   K...